Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sunvozertinib plus Anlotinib in EGFR-mutated NSCLC (WUKONG-32)
NCT06348927Phase 2
Key facts
- Status
- Recruiting
- Start
- Jul 2024
- Primary completion
- Oct 2025
- Countries
- 1
- Sponsor
- Hunan Cancer Hospital
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Drugs
- sunvozertinib
- Conditions
- non-small cell lung cancer (NSCLC)
01
Overview
Phase 2, open-label, single-arm trial of sunvozertinib in non-small cell lung cancer (NSCLC), sponsored by Hunan Cancer Hospital. Primary endpoint: Progression-Free Survival at 36 months. Started Jul 2024; status: recruiting.
02
Design
1 arm- Study design
- Non-randomizedOpen-labelSingle group
Experimental group
Sunvozertinib + Anlotinib
03
Who it enrols
Patients with locally advanced or metastatic NSCLC, EGFR-sensitive mutations (19del, L858R, T790M) combined with co-mutations, and no prior systemic therapy for advanced disease.
04
Endpoints
Primary
Progression-Free Survival
Secondary
Objective Response Rate
Overall Survival
Duration of Response
Adverse Events
Beyond the preview
Go deeper on NCT06348927.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06348927.